Blinded designs for disulfiram research prevent the evaluation of the crucial aspect differentiating the disulfiram and control groups, the psychological threat. Blinding distributes the threat evenly amongst the arms of a study, whereas open-label trials allow the psychological threat to be present in only the disulfiram arm compared to controls. For this reason, we did not include blinded RCTs in our meta-analyses for the subgroups supervision, cocaine, and various controls.
